Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Why Beam Therapeutics Stock Tanked on Tuesday
05:05pm, Tuesday, 06'th May 2025
Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
09:20am, Tuesday, 06'th May 2025
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago.
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Tuesday, 06'th May 2025
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BE
New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3)
Power Ranking Our Top Stock Picks of 2025
10:47am, Tuesday, 01'st Apr 2025
Subscribers to Chart of the Week received this commentary on Sunday, March 30.
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
02:25pm, Monday, 31'st Mar 2025
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
10:30am, Friday, 28'th Mar 2025
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S.
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
01:13pm, Friday, 21'st Mar 2025
Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
03:21pm, Tuesday, 18'th Mar 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
01:10pm, Tuesday, 11'th Mar 2025
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 an
Beam Therapeutics Announces Pricing of Underwritten Offering
06:01am, Monday, 10'th Mar 2025
CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pri
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across I
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
11:45am, Wednesday, 26'th Feb 2025
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
